BIIB Live signals | Maximize Profits with Getagraph.com

SELL 6646 min ago

@ $212.34

Issued: 29 May 2024 @ 11:21

Return: 5.94%

Previous signal: May 29 - 09:30

Previous signal: Buy

Return: -1.70 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.82M
Average Volume	1.22M
Market Cap	32.75B
EPS	$0 ( 2024-04-24 )
Next earnings date	( $3.98 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	28.08
ATR14	$7.49 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Keeney Adam	Sell	938	Restricted Stock Unit
2024-05-01	Keeney Adam	Buy	938	Common Stock
2024-05-01	Keeney Adam	Sell	276	Common Stock
2024-04-02	Singhal Priya	Sell	93	Common Stock
2024-04-01	Murphy Nicole	Buy	240	Common Stock

INSIDER POWER
2.12
Last 100 transactions
Buy: 75 037 \| Sell: 71 550

Volume Correlation

Long: 0.65 (moderate)

Short: 0.66 (moderate)

Signal:(59) Neutral

Biogen Inc Correlation

10 Most Positive Correlations
OZEM	1
KYTX	0.935
CHMG	0.934
GBLMX	0.933
AIXI	0.928
INTJ	0.924
RENB	0.923
IRDM	0.92
HTZWW	0.918
NTRP	0.918

10 Most Negative Correlations
CALC	-0.946
FAAR	-0.93
RENE	-0.929
BRKHW	-0.922
ATMV	-0.918
FEBO	-0.917
DECAU	-0.914
JSPR	-0.901
JAJWX	-0.9
MCAAW	-0.899

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biogen Inc Correlation - Currency/Commodity

0.62
( weak )

0.64
( weak )

-0.34
( neutral )

0.48
( neutral )

-0.43
( neutral )

Biogen Inc Financials

Annual	2023
Revenue:	$9.84B
Gross Profit:	$7.30B (74.24 %)
EPS:	$8.02

FY	2023
Revenue:	$9.84B
Gross Profit:	$7.30B (74.24 %)
EPS:	$8.02

FY	2022
Revenue:	$10.17B
Gross Profit:	$7.90B (77.61 %)
EPS:	$20.97

FY	2021
Revenue:	$10.98B
Gross Profit:	$8.87B (80.79 %)
EPS:	$10.44

Financial Reports:

No articles found.

Biogen Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.